Nibal Betari

Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer’s Disease

Angela De Simone, Valeria La Pietra, Nibal Betari et al. · ACS Medicinal Chemistry Letters · 2019 · 56 citations · Full text

Life Sciences, Medicinal Chemistry, Neuroscience +17

Design, Synthesis and Multitarget Biological Profiling of Second-Generation Anti-Alzheimer Rhein–Huprine Hybrids

F. Javier Pérez-Areales, Nibal Betari, Antonio Viayna et al. · Future Medicinal Chemistry · 2017 · 51 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer

Elena Catanzaro, Nibal Betari, José M. Arencibia et al. · European Journal of Medicinal Chemistry · 2020 · 41 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics

Richard Ågren, Nibal Betari, Marcus Saarinen et al. · The International Journal of Neuropsychopharmacology · 2023 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations

Nibal Betari, Kristoffer Sahlholm, Xavier Morató et al. · Frontiers in Pharmacology · 2020 · 19 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15